Voreloxin | SNS-595 | Vosaroxin | CAS#175414-77-4

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

Other drug agents
Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

Voreloxin

Descrpition of Voreloxin (SNS-595, Vosaroxin): Voreloxin (formerly known as SNS-595 or Vosaroxin) is a small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. This agent shows a favorable toxicity profile in several aspects: it does not generate reactive oxygen species, as do anthracyclines, reducing the risk of cardiotoxicity; it is not a P-glycoprotein (P-gp) substrate, and thereby evades the common mechanism for multidrug resistance; and it has limited distribution to normal tissues and a more chemically stable molecular structure. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer: Dainippon Pharmaceutical (Originator), Sunesis (Licensee)

MedKoo Code#: 202650
Name: Voreloxin
CAS#: 175414-77-4. Synonym: SNS 595; SPC-595; AG-7352; Voreloxin; Vosaroxin IUPAC/Chemical name: 7-((3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Chemical structure:	Theoretical analysis :
	Chemical Formula: C18H19N5O4S Exact Mass: 401.11577 Molecular Weight: 401.44 m/z: 401.11577 (100.0%), 402.11913 (19.5%), 403.11157 (4.5%), 402.11281 (1.8%), 403.12248 (1.8%) Elemental Analysis: C, 53.85; H, 4.77; N, 17.45; O, 15.94; S, 7.99
Availability and price: Voreloxin (SNS-595) is available through custom synthesis To inquire the quotation and lead time of custom synthesis for this agent, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.
Quality control data: Product will be shipped with supporting analytical data.

Information about this agent

SNS-595 is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously in the treatment of cancer. Sunesis researchers conducted in vitro and cell-based studies elucidating SNS-595's mechanism of action. SNS-595 selectively intercalates DNA and poisons topoisomerase II, resulting in replication-dependent DNA damage, irreversible G2 arrest and rapid apoptosis. SNS-595's targeted DNA-topoisomerase II interactions may contribute to the broad therapeutic window observed in patients treated with SNS-595. SNS-595 avoids common drug resistance pathways and may have advantages over other topoisomerase poisons

References:

1: Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metab Dispos. 2009 Mar;37(3):594-601. Epub 2008 Dec 12. PubMed PMID: 19074528.

2: Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. Epub 2008 Oct 19. PubMed PMID: 18931998.

3: Mills DA, Fekrazad HM, Verschraegen CF. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers. Curr Opin Investig Drugs. 2008 Jun;9(6):647-57. Review. PubMed PMID: 18516764.

4: Srivastava SK, Jha A, Agarwal SK, Mukherjee R, Burman AC. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med Chem. 2007 Nov;7(6):685-709. Review. PubMed PMID: 18045063.

5: Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem. 2004 Apr 8;47(8):2097-109. PubMed PMID: 15056007.

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)